The Biden administration has asked Jill Biden to spearhead a White House effort to find new ways for the federal government to boost women’s health. The first-of-its-kind initiative will focus on enhancing research into women’s health issues.
Though there are more women than men in the US, women have been neglected for far too long in health research, according to President Joe Biden, who recently announced a new initiative by his administration seeking to change that.
On Monday, Biden established the first-ever White House Initiative on Women’s Health Research, which focuses all government health agencies on...
Quantitative CT from two platforms, Brainomix’s e-Lung and a UCLA algorithm, both detected nintedanib’s effect in the Phase III INBUILD substudy. Brainomix’s Peter George said e-Lung’s reticulovascular score alone predicted later mortality, but FVC remains the regulator’s primary endpoint.
Elixir Medical’s first individual patient data analysis from 2,885 patients of its two randomized trials points to a sustained advantage over Medtronic’s Resolute Onyx, especially in ACS and LAD lesions.
Sales growth for the pharma giant's Alzheimer's drug proves that blood biomarkers provide business benefits in this difficult area.
Alzheimer’s blood testing is moving into primary care clinics faster than clear guidance for how to integrate the tests. Four experts discussed the clinical, technological and policy challenges in implementing blood-based biomarkers for the disease at the AdvaMed MedTech Conference.
Resmed’s Q1 revenue rose 6% to $1.4bn as sleep and mask sales grew, offsetting the Astral ventilator recall. With Astral sales ending permanently and MatrixCare sold, the company is refocusing on sleep and related conditions.
Stryker cut 2026 organic growth guidance to 6.5–7% as softer hip and knee procedure trends, vascular supply constraints and caution on capital execution weighed on results. A cyberattack and SAP rollout clouded its view; management points to 2027 launches to grow at the high end of its markets.
Dexcom said losing preferred status on a pharmacy benefit manager (PBM) formulary affects less than 4% of US revenue and should have a limited effect on 2027 results. It plans to launch a patient access service, originally built for Medicare coverage expansion, early next year.
